

- van Iterson, M., 95
 van Zundert, A., 509
 Vandegriff, K.D., 339
 Vanlal, D., 584
 Vemgal, P., 755
 Ventura, J.L., 166
 Vezina, D.P., 447
 Vijayakumar, A., 131
 Vincent, C., 223, 384
 Virmani, S., 298
 Vitali, E., 87
 Vogel, A., 188
 Vricella, L.A., 215
- Waddell, T.K., 850
 Wagener, G., 195
 Waldron, P.E., 679
 Wall, M.H., 711
 Walsh, E.K., 569
 Walther, T., 286
 Wang, S., 195
 Warltier, D.C., 619, 651
 Warren, O.J., 223, 384
- Wasnick, J.D., 54, 358
 Wasowicz, M., 828
 Watanabe, I., 379
 Watret, A.L., 384
 Weeks, D., 41
 Wei, L., 360, 381
 Weihrauch, D., 619
 Weis, F.C., 203
 Weis, M., 203
 White, C.M., 22
 Wiesenack, C., 182
 Willcox, T., 886
 Wilner, G., 336
 Windokun, A., 77
 Winslow, R.M., 339
 Wolfe, Y., 569
- Xu, G., 757
 Xu, M., 479, 766
- Yamaguchi, S., 853
 Yamazaki, T., 275, 926
 Yap, C.-H., 672
- Yazigi, A., 444, 582
 Yee, J., 846
 Yokote, J., 379
 Yoon, J.H., 639
 Yoon, S.Z., 646
 Yoon, S.M., 646
 Young, M.A., 339
 Youssef, G., 658
 Yu, Q., 789
 Yuge, O., 822
 Yun, J., 513
 Yusim, Y., 348
- Zaky, S.S., 479
 Zangrillo, A., 34, 147, 280, 474, 594 625,
 758, 807, 813
 Zeyneloglu, P., 580
 Zhang, H., 484
 Zhang, Y., 495
 Zimmermann, A., 929
 Zvara, D.A., 112

SUBJECT INDEX

- Abscess, aortic valve, 561–563
 ABSORB trial, 5–6
 Acidosis, lactic, during cardiac surgery, 407–416, 711–719
 Activated protein C, for cardiac surgery, 858–859
 Air embolism, in cardiac surgery, three-dimensional echocardiographic assessment of, 705–707
- Airway
 injury of, persistent pneumothorax after, 369–372
 stenosis of, in cardiac surgery, 658–662
 Alveolar recruitment, in one-lung ventilation, 506–508
 Aminocaproic acid, clinical trials of, 2–3
 Anabolic steroids, cardiac abnormalities due to, 208–210
 Anesthesiology, intensive care training in, 110–114
 Aneurysm
 aortic
 after coarctation repair, 256–258
 partial left-heart bypass for, 893–900
 repair of, transesophageal echocardiography during, 71–74
 aortic root, surgery for, 571–572
 sinus of Valsalva, 421–423, 735–737
 ventricular, 118–120
 Angiography, for coronary artery graft patency verification, 232–233
 Angioplasty, carotid, vs. endarterectomy, 245–250
 Animal studies
 hemodilution agents, 339–347
 preconditioning, 4
 beta-adrenergic receptors and, 607–613
 helium for, opioid receptor effects on, 619–624
 timing of, 600–606
 xenon effects on, 614–618
 transcatheter valve replacement, 5
 Antegrade cerebral perfusion, in aortic arch surgery, 417–420
 Anticoagulant therapy, for ventricular assist devices, 743
 Antioxidants, as anti-inflammatory agent, for cardiopulmonary bypass, 386
- Aorta
 aneurysm of
 after coarctation repair, 256–258
- Aorta (*Continued*)
 partial left-heart bypass for, 893–900
 repair of, transesophageal echocardiography during, 71–74
 bypass in, 893–900
 coarctation of
 in moyamoya disease, 206–207
 repair of, aneurysm after, 256–258
 cross-clamping of
 pathogenic effects of, 229
 release of, 79–81
 dissection of, 427–428, 732–734
 embolism in, from atrial myxoma, 211–214
 transesophageal echocardiography of, 694–701
- Aortic arch
 repair of
 cerebral protection in, 417–420
 intensive care length of stay after, 789–794
 mechanical ventilation risk factors in, 495–500
 transesophageal echocardiography of, 697–699
- Aortic root
 aneurysm of, 571–572
 ulcer of, 564–565
- Aortic valve
 bicuspid, repair of, 570–571
 calcification of, in kidney failure, 253–255
 insufficiency of, in kidney failure, 253–255
 preservation of, 571–572
 prosthetic, endocarditis of, 561–563
 regurgitation of, 561–563, 732–734
 patient-prosthesis mismatch in, 572
 surgery for, 571–572
 valve replacement for, 855–857
 repair of
 classification of, 571
 intraoperative assessment of, 79–81
 respiratory function after, 795–801

- Aortic valve (*Continued*)
 replacement of
 advances in, 572–574
 brain natriuretic peptide levels after, 161–165
 epicardial echocardiography in, 292–297
 in Morquio syndrome, 855–857
 percutaneous, 280–285, 286–291
 pulmonary edema after, extracorporeal membrane oxygenation for, 549–554
 right atrial fistula after, 360–363
 transcatheter, 573–574
 stenosis of
 during CABG surgery, 869–877
 in kidney failure, 253–255
 with low transvalvular pressure gradient, 573
 replacement of, 572–573
 surgery for, 280–285, 286–291, 292–297, 572–573
 valve replacement for, 5
- Aortopulmonary fistula, after coarctation repair, 256–258
- Apgar score, in vascular surgery, 433
- Aprotinin
 as anti-inflammatory agent, for cardiopulmonary bypass, 385–386
 refractory shock due to, hemofiltration for, 526–528
 safety profile of, 2–3
- Arndt bronchial blocker, 501–505, 862, 866–867
- Arrhythmias. *See* Cardiac arrhythmias
- Arterial oxygenation, in one-lung ventilation, 770–774
- Artifacts, motion, in radiography, 909–910
- Aspirin, platelet resistance to, 6
- Aspirin and Tranexamic Acid for Coronary Artery Surgery trial, 3
- Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography (ACCURACY) trial, 260–261
- Atenolol, for noncardiac surgery, clinical trials of, 684–687
- Atherosclerosis
 aortic, dissection of, 427–428
 coronary, treatment of, literature review of, 259–265
- Atrial fibrillation, after cardiac surgery
 transfusion effects on, 22–27
 white blood cell count and, 484–487
- Atrial Fibrillation Suppression Trials, 22–27
- Atrial flutter, ablation of, airway interventions for, 841–845
- Atrial natriuretic peptide, for kidney dysfunction prevention, 151–160
- Atrial septum, myxoma of, 424–426
- Atrial tachycardia, ablation of, airway interventions for, 841–845
- Atrio-biventricular pacing, after CABG surgery, 306–311
- Atrio-right ventricular pacing, after CABG surgery, 306–311
- Atrium
 left
 inverted appendage of, 914–915
 thrombus of, 566–568
 lipoma in, 729–731
 myxomas of
 embolism from, 211–214
 in septum, 424–426
 transesophageal echocardiography in, 66–68
 right, fistula of, after aortic valve replacement, 360–363
 sinus of Valsalva aneurysm rupture into, 735–737
- B cells, in cardiopulmonary bypass pathogenesis, 228
- BART (Blood Conservation using Antifibrinolytics) trial, 2–3
- Beta blockers, for preconditioning, 432–433, 625–632
- Beta-adrenergic receptors, in desflurane-induced preconditioning, 607–613
- Bicuspid aortic valve, repair of, 570–571
- Bisoprolol, for noncardiac surgery, clinical trials of, 684–693
- Bispectral index
 during propofol sedation, 182–187
 during propofol-remifentanyl anesthesia, 175–181
- Bleeding and blood loss. *See also* Transfusions
 clopidogrel-induced, 263
 in hemodilution, 339–347
 intracranial, cerebrovascular autoregulation measurement in, 215–218
 during or after cardiac surgery
 activated protein C for, 858–859
 recombinant activated factor VII therapy for, 828–834
 recombinant factor VIIa for, 28–33, 34–40
 tranexamic acid for, 312–315
 prevention of, salvage methods for, 394–400
- Blood conservation, for cardiopulmonary bypass, 388
- Blood Conservation using Antifibrinolytics (BART) trial, 2–3
- Blood pressure, abnormal. *See* Hypertension
- Blood transfusions. *See* Transfusions
- Bodybuilding, anabolic steroid use for, cardiac abnormalities due to, 208–210
- Brain
 hemorrhage in, cerebrovascular autoregulation measurement in, 215–218
 perfusion of, antegrade, deep hypothermic circulatory arrest with, in aortic arch surgery, 495–500
 protection of, in aortic arch repair, 417–420
- Brain natriuretic peptide, in cardiac surgery
 epidural anesthesia effects on, 807–812
 as heart failure predictor, 161–165
 for kidney dysfunction prevention, 151–160
 postoperative, 147–150
- Bronchial blockers
 vs. left-sided double-lumen tube, 501–505
 for one-lung ventilation, 860–868
- Bronchial injury, persistent pneumothorax after, 369–372
- Bronchoscopy
 for bronchial blockers, 863
 pneumonia risk with, 780–788
- Bulla, in lung, 911–913
- CABG surgery. *See* Coronary artery bypass graft (CABG) surgery
- Calcification
 of heart valves, in kidney failure, 253–255
 of papillary muscle, 118–120
- Capillary density, ketanserin effects on, 95–101
- Carbon dioxide, end-tidal, in one-lung ventilation, 775–779
- Carbon monoxide
 for cardiopulmonary bypass, 388–389
 endogenous, in cardiopulmonary bypass, 802–806
- Carboxyhemoglobin
 in banked blood supply, 336–338
 in cardiopulmonary bypass, 802–806
- Cardiac arrhythmias
 ablation of, airway interventions for, 841–845
 electrophysiologic testing of, ketamine for, 373–378
- Cardiac catheterization, for aortic valve replacement, 280–285, 286–291
- Cardiac output monitoring
 FloTrac/Vigileo device for, 401–406
 ultrasound dilution method for, 836–840
- Cardiac resynchronization therapy, for heart failure, 741
- Cardiac support, extracorporeal membrane oxygenation for, 886–892
- Cardiac surgery. *See also specific procedures*
 with acute intermittent porphyria, 364–368

- Cardiac surgery. *See also specific procedures (Continued)*
 advances in, 430–436
 antifibrinolytics for, 2–3
 aortic stenosis discovery during, 869–877
 atrial fibrillation after, white blood cell count and, 484–487
 blood loss in
 activated protein C for, 858–859
 in hemophilia A, activated factor VII for, 679–681
 monitoring with thromboelastography, 828–834
 recombinant factor VIIa for, 28–33, 34–40
 blood pressure control in, ketanserin for, 95–101
 blood transfusion requirements for, preoperative immune response and, 330–335
 brain natriuretic peptide levels after, 147–150, 161–165
 carbon monoxide production during, 802–806
 cardiac output monitoring in, 401–406
 cardioprotection for. *See* Preconditioning
 cardiopulmonary bypass for. *See* Cardiopulmonary bypass
 cerebral protection in, 417–420
 for congenital heart disease
 cerebrovascular autoregulation measurement in, 215–218
 congenitally corrected, 239–244
 C-reactive protein levels after, 166–169
 delirium after, ketamine for, 651–657
 in elderly persons, epidural anesthesia for, 807–812
 extubation timing in, 348–357
 focused transthoracic echocardiography in, 450–456
 gaseous embolism in, 705–707
 glycemic control in, 901–908
 graft blood blow after, milrinone effects on, 48–53
 Guillain-Barré syndrome after, 82–83
 in heart failure, mortality in, 741–742
 incisions for, vs. respiratory function, 795–801
 intensive care length of stay after, 789–794
 internal jugular vein cannulation for, mediastinal hematoma due to, 682–683
 intra-aortic balloon pump in, 479–483
 intraoperative assessment of, 79–81
 intraoperative blood salvage in, 394–400
 kidney dysfunction after, preventive natriuretic peptide for, 151–160
 after kidney transplantation, 8–13
 lactate levels after, 663–667
 lactic acidosis during, 407–416, 711–719
 left atrial “v” waves after, 69–70
 in left ventricular dysfunction, propofol pharmacokinetics in, 182–187
 levosimendan in, 474–478
 lipocalin levels in, 195–199
 memory processing during, in propofol-remifentanyl anesthesia, 175–181
 minimally invasive, reimbursement for, 142–146
 in Morquio syndrome, 855–857
 for moyamoya disease, 206–207
 multisystem organ failure in, ethyl pyruvate effects on, 324–329
 myocardial functional assessment in, 462–467
 myocardial protection in. *See* Preconditioning
 pacing after, 306–311
 parainfluenza virus pneumonia after, 84–86
 postoperative pain management in, 170–174
 preconditioning for. *See* Preconditioning
 propofol for, 878–885
 pulmonary artery flow patterns after, 54–61
 right atrial fistula after, 360–363
 robotically assisted, 407–416
 spinal analgesia in, 813–821
- Cardiac surgery. *See also specific procedures (Continued)*
 sponge-induced instability after, 102–109
 statins before or after, 263, 431–432, 468–473, 633–638
 status epilepticus after, near-infrared spectroscopy detection of, 668–671
 subglottic stenosis related to, 658–662
 systemic inflammatory response to
 erythropoietin effects on, 316–323
 treatment of, 431–432
 tranexamic acid for, 312–315
 transesophageal echocardiography in, complications of, 62–65
 transfusions for, atrial fibrillation development and, 22–27
 tricuspid regurgitation after, 251–252
 urinary nitric oxide products during, 188–194
 for valvular disease. *See* Valvular heart disease, surgery for
 for ventricular septal defect, left ventricular-to-right atrial shunt in, 675–678
 wound infection after, epidemiology of, 488–494
- Cardiomyopathy, noncompaction, 200–202
- Cardioprotection, preconditioning for. *See* Preconditioning
- Cardiopulmonary bypass
 with acute intermittent porphyria, 364–368
 alternatives to, 389
 aortic dissection during, 427–428
 blood transfusion requirements for, preoperative immune response and, 330–335
 carbon monoxide production in, 802–806
 conversion to, during robotically assisted surgery, 407–416
 C-reactive protein levels after, 166–169
 delirium after, ketamine for, 651–657
 Guillain-Barré syndrome after, 82–83
 inflammatory response to
 in Korean population, 646–650
 pathogenesis of, 223–231
 sevoflurane effects on, 639–645
 treatment of, 384–393, 431–432
 kidney dysfunction after, preventive natriuretic peptide for, 151–160
 lactic acidosis during, 711–719
 for moyamoya disease, 206–207
 multisystem organ failure in, ethyl pyruvate effects on, 324–329
 rewarming strategies for, 14–21
 systemic inflammatory response to, erythropoietin effects on, 316–323
 urinary nitric oxide products during, 188–194
 weaning from, extracorporeal membrane oxygenation for, 886–892
- Carotid arteries
 angioplasty for, 245–250
 stents for, 245–250
 transesophageal echocardiography of, 697–698
- Carotid endarterectomy
 anesthetic technique for, 432
 treatment options for, 245–250
- Catheter
 central venous. *See* Central venous catheter
 pulmonary, kidney injury from, 379–380
- Cavopulmonary shunt pressure, in congenital heart disease, 215–218
- Celiac artery, transesophageal echocardiography of, 699–700
- Cell adhesion molecule, in cardiopulmonary bypass pathogenesis, 228
- Central venous catheter
 insertion of, ultrasonography for, 720–728
 position of, verification of, 457–461
 venous perforation by, mediastinitis due to, 672–674
- CentriMag VAD, for myocarditis, 87–94

- Cerebral perfusion
 antegrade, deep hypothermic circulatory arrest with, in aortic arch surgery, 495–500
 protection of, in aortic arch repair, 417–420
- Cerebrovascular autoregulation measurement, in congenital heart disease, 215–218
- Cervical spine lesions, shoulder pain due to, 853–854
- Chest radiography
 for giant bullous emphysema, 911–913
 motion artifacts in, 909–910
- Chest wall
 deformity of, repair of, inferior vena cava obstruction after, 515–517
 resection of, for fibrous dysplasia, 518–521
- Chronic obstructive pulmonary disease, femoral thrombectomy in, 522–525
- Circulatory support
 for myocarditis, 87–94
 three-dimensional echocardiographic assessment of, 702–710
- Clevidipine, for hypertension, 3
- Clinical trials
 of aminocaproic acid, 2–3
 of perioperative beta-blockade, in noncardiac surgery, 684–693
- Clopidogrel
 before CABG surgery, 263
 platelet resistance to, 6
- Coagulation, measurement of, methemoglobin and, 41–47
- Coagulation factors, in cardiopulmonary bypass pathogenesis, 224–225
- Coarctation, aortic
 in moyamoya disease, 206–207
 repair of, aneurysm after, 256–258
- Cognitive function and dysfunction
 after CABG surgery
 ketamine for, 651–657
 rewarming and, 14–21
 during propofol-remifentanyl anesthesia, 175–181
 ventricular assist devices and, 743
- Cohen endobronchial blocker, 501–505, 862–863
- Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial, 741
- Complement, in cardiopulmonary bypass pathogenesis, 225–226
- Complement inhibitors, for cardiopulmonary bypass, 386
- Computed tomography angiography, in coronary artery disease, 260–262
- Congenital heart disease
 cerebrovascular autoregulation measurement in, 215–218
 noncompaction cardiomyopathy, 200–202
 surgery for
 aortic aneurysm after, 256–258
 congenitally corrected, 239–244
 intraoperative assessment of, 79–81
 lactate levels after, 663–667
 left atrial “v” waves after, 69–70
 pulmonary artery flow patterns after, 54–61
 in Shone’s anomaly, 75–76
 status epilepticus after, 668–671
 subglottic stenosis related to, 658–662
 for ventricular septal defect, left ventricular-to-right atrial shunt in, 675–678
- Contact activation, in cardiopulmonary bypass pathogenesis, 223–231
- Continuity equation, for aortic stenosis, 873
- Continuous positive airway pressure, for orthopnea, 522–525
- Coronary angiography
 in coronary artery disease, 260–262
 in coronary artery graft patency verification, 232–233
- Coronary artery(ies)
 anomalous, 696
 stents for
 drug-eluting, 5–6
 outcomes of, 261–262
 transesophageal echocardiography of, 694–696
- Coronary artery bypass graft (CABG) surgery
 with acute intermittent porphyria, 364–368
 antifibrinolytics for, 2–3
 aortic stenosis discovery during, 869–877
 atrial fibrillation after, white blood cell count and, 484–487
 B-natriuretic peptide after, 147–150
 for congenitally corrected transposition of the great arteries, 239–244
 C-reactive protein levels after, 166–169
 in elderly persons, epidural anesthesia for, 807–812
 graft blood blow after, milrinone effects on, 48–53
 graft patency verification in, 232–238
 Guillain-Barré syndrome after, 82–83
 internal jugular vein cannulation for, mediastinal hematoma due to, 682–683
 intra-aortic balloon pump in, 479–483
 intraoperative blood salvage in, 394–400
 kidney dysfunction after, preventive natriuretic peptide for, 151–160
 multisystem organ failure in, ethyl pyruvate effects on, 324–329
 myocardial functional assessment in, 462–467
 neurocognitive function after, 14–21
 off-pump
 inflammatory response in, 389
 lipocalin levels in, 195–199
 outcomes of, 262
 tranexamic acid for, 312–315
 outcomes of, 261–263
 pacing after, 306–311
 postoperative pain management in, 170–174
 preconditioning for. *See* Preconditioning
 propofol for, 878–885
 rewarming strategies for, 14–21
 robotically assisted, 407–416
 spinal analgesia in, 813–821
 sponge-induced instability after, 102–109
 statins before or after, 263, 431–432, 468–473, 633–638
 vs. stents, 261–262
 systemic inflammatory response to
 erythropoietin effects on, 316–323
 treatment of, 431–432
 transesophageal echocardiography in, complications of, 62–65
- Coronary artery disease, treatment of, literature review of, 259–265
- Coronary Artery Evaluation Using 64-Row Multidetector Computed Tomography Angiography (CORE 64) trial, 260–261
- Coronary ostium, left, occlusion of, in aortic dissection, 732–734
- Coronary sinus of Valsalva, aneurysm of, 421–423
- Corticosteroids, as anti-inflammatory agent, for cardiopulmonary bypass, 384–385, 431
- C-reactive protein, after cardiac surgery, 166–169
- Cyclosporine, for heart transplantation, 744
- Cytokines
 blockade of, for cardiac surgery, 432
 in cardiopulmonary bypass pathogenesis, 227–229
 in Korean population, 646–650
 sevoflurane effects on, 639–645

- Deep hypothermic circulatory arrest, in aortic arch surgery, 417–420, 495–500, 789–794
- Delirium, after cardiac surgery, ketamine for, 651–657
- Desflurane, for preconditioning
 beta-adrenergic receptors and, 607–613
 mortality rate from, 594–599
 timing of, 600–606
- Dexamethasone, as anti-inflammatory agent, for cardiopulmonary bypass, 431
- Diabetes mellitus, glycemic control in, 901–908
- Diagnosis-related groups, in Germany, 142–146
- Dissection, aortic, 427–428
- Doppler technology
 for aortic stenosis, 871–873
 for coronary artery graft patency verification, 236
- Double-blocker technique, for one-lung ventilation, 866
- Echocardiography
 for aortic stenosis, 869–877
 for coronary artery graft patency verification, 236
 focused transthoracic, 450–456
 for inverted left atrial appendage, 914–915
 for mechanical circulatory support, for myocarditis, 87–94
 three-dimensional, for left ventricular assist device assessment, 702–710
 transesophageal. *See* Transesophageal echocardiography
- Edema, pulmonary
 after aortic valve replacement, extracorporeal membrane oxygenation for, 549–554
 in atrial myxoma embolism, 211–214
- Editorials
 An American View--American and European Anesthesia Reimbursement Policies' Effects on the Adoption of Novel Techniques, 140–141
 Cardioprotection by Volatile Anesthetics: Established Scientific Principle of Lingering Clinical Uncertainty?, 589–593
 Catheter-Based Aortic Valve Replacement, 277–279
 A European View--Managed Care Health Plans: Better or Cheaper Treatment Strategies?, 137–139
 Perioperative Transthoracic Echocardiography: "Universal Acid"?, 447–449
 The Role of the Anesthesiologist in Thoracic Surgery: We Can Make a Difference!, 761–765
- Education
 in intensive care training, 110–114
 for transesophageal echocardiography, 544–548
- Elderly persons, cardiac surgery in, epidural anesthesia for, 807–812
- Electrocardiography, after mitral valve replacement, 69–70
- Electrophysiologic testing
 airway interventions for, 841–845
 ketamine for, 373–378
- Embolism
 from atrial myxoma, 211–214
 gaseous, three-dimensional echocardiographic assessment of, 705–707
 pulmonary, in right heart failure, 741
 tumor
 in inferior vena cava, 77–78
 in pneumonectomy, 219–222
- Emphysema, giant bullous, 911–913
- Endarterectomy, carotid
 anesthetic technique for, 432
 treatment options for, 245–250
- Endobronchial blockers, for one-lung ventilation, 860–868
- Endocarditis, of prosthetic aortic valve, 561–563
- Endoscopic cardiac surgery, reimbursement for, 142–146
- Endothelial cells, in cardiopulmonary bypass pathogenesis, 227
- Endothelin(s), blockade of, for cardiac surgery, 432
- Endotoxin, in cardiopulmonary bypass pathogenesis, 229
- Endotracheal tube
 vs. bronchial blockers, for one-lung ventilation, 860–868
 double-lumen, for one-lung ventilation, 501–505
 removal of
 in pediatric patients, 348–357
 pneumonia risk and, 780–788
 after thoracotomy, 766–769
 for tracheal injury management, 513–514
- End-tidal carbon dioxide, in one-lung ventilation, 775–779
- Enoximone, for heart failure, 741
- Epicardial ultrasonography, for coronary artery graft patency verification, 236
- Epidural anesthesia
 for coronary artery bypass graft surgery, in elderly persons, 807–812
 for lung resection, extubation and, 766–769
- Erythropoietin, for systemic inflammatory response, after CABG surgery, 316–323
- Escherichia coli* pneumonia, in cardiothoracic intensive care unit, 780–788
- Esmolol, for preconditioning, 625–632
- Esophagectomy, high-frequency jet ventilation for, 509–512
- Esophagus, perforation of, in transesophageal echocardiography, 62–65
- Ethyl pyruvate effects, for multisystem organ failure prevention, 324–329
- Exercise
 anabolic steroid use for, cardiac abnormalities due to, 208–210
 atrial myxoma embolism during, 211–214
- Extracorporeal membrane oxygenation
 for cardiac graft failure, 203–205
 for myocarditis, 87–94
 for severe cardiac and respiratory disease, 886–892
- Extubation. *See* Endotracheal tube, removal of
- Factor(s), in cardiopulmonary bypass pathogenesis, 224–225
- Factor VIIa
 for blood loss, in cardiac surgery, 28–33, 34–40
 for hemophilia A, during ventricular septal defect repair, 679–681
 monitoring with thromboelastography, 828–834
- Fellowship training, in intensive care, 110–114
- Femoral thrombectomy, in obesity with chronic obstructive pulmonary disease, 522–525
- Femoropopliteal artery, stenting of, 432–433
- Fibrinolysis, in cardiopulmonary bypass pathogenesis, 226–227
- Fibroelastomas, of pulmonic valve, 358–359
- Fibrous dysplasia, chest wall resection for, 518–521
- Filters, vena cava, intracardiac migration of, 381–383
- Fistula
 after coarctation repair, 256–258
 right atrial, after aortic valve replacement, 360–363
- FloTrac/Vigileo device, for cardiac output monitoring, 401–406
- Flowmetry, for coronary artery graft patency verification, 234–237
- Fluoroscopy, for coronary artery graft patency verification, 233–234
- Fontan procedure, pulmonary artery flow patterns after, 54–61
- Foreign bodies, retained, hemodynamic instability due to, 102–109
- Gaseous embolism, in cardiac surgery, three-dimensional echocardiographic assessment of, 705–707
- General anesthesia
 cardiac output measurement during, 836–840
 for electrophysiology procedures, 841–845
- General Anesthesia versus Local Anesthesia, for carotid endarterectomy, 432

- Giant bullous emphysema, 911–913
- Glycemic control, perioperative, 901–908
- Gorlin formula, for aortic stenosis, 873–874
- Granule membrane protein-140 receptor, in cardiopulmonary bypass pathogenesis, 228
- Guillain-Barré syndrome, after cardiopulmonary bypass, 82–83
- Heart**
 surgery on. *See* Cardiac surgery; *specific procedures*
 transplantation of. *See* Transplantation, heart
- Heart failure**
 after aortic valve replacement, brain natriuretic peptide and, 161–165
 diagnosis of, 739
 diastolic, 740–741
 extracorporeal membrane oxygenation for, 886–892
 heart transplantation for, 743–745
 in noncompaction cardiomyopathy, 200–202
 right, 741, 742
 treatment of, progress in, 738–743
- HeartMate II, three-dimensional echocardiographic assessment of, 704
- HeartMate XVE, three-dimensional echocardiographic assessment of, 702–703
- Hematoma, mediastinal, due to internal jugular vein cannulation, 682–683
- Hemodilution**
 agents for, 339–347
 ultrafiltration effects on, 387
- Hemodynamics**
 alveolar recruitment effects on, 506–508
 after CABG surgery, pacing impact on, 306–311
 ketanserin effects on, 95–101
 in mitral valve replacement with pulmonary hypertension, 298–305
 retained surgical sponge effects on, 102–109
- Hemofiltration, for aprotinin-induced refractory shock, 526–528
- Hemophilia A, ventricular septal defect repair in, activated factor VII for, 679–681
- Hemorrhage. *See* Bleeding and blood loss
- Hemospan, for hemodilution, 339–347
- Hemostasis, after CABG surgery, tranexamic acid for, 312–315
- Heparin**
 for cardiopulmonary bypass, 386–387
 for ventricular assist devices, 743
- High-frequency jet ventilation, for off-pump single-lung transplantation, 846–849
- Highlights from 2008, 1–7
- Horner's syndrome, due to mediastinal schwannoma, 115–117
- Hydroxyethyl starch, for hemodilution, 339–347
- Hyperglycemia, after cardiac surgery, 433
- Hypertension**
 pulmonary
 after mitral valve replacement, 69–70
 mitral valve replacement with, 298–305
 systemic
 clevidipine for, 3
 ketanserin for, 95–101
- Hypothermia**
 in aortic arch repair, 417–420, 789–794
 in aortic arch surgery, 495–500
 in cardiopulmonary bypass, 206–207, 388
- Hypoxemia, in one-lung ventilation, 850–852
- Immune response, preoperative, transfusion requirements and, 330–335
- Immunosuppressive therapy, for heart transplantation, 744–745
- Impella Recover 100 device, for myocarditis, 87–94
- Induction therapy, for heart transplantation, 744–745
- Infants**
 cardiac surgery in
 status epilepticus after, 668–671
 subglottic stenosis related to, 658–662
 ventricular septal defect repair, 679–681
 congenital heart disease in, cerebrovascular autoregulation measurement in, 215–218
 newborn, surgery in, subglottic stenosis related to, 658–662
- Infections**
 after cardiac surgery, epidemiology of, 488–494
 mediastinal, due to central venous catheter venous perforation, 672–674
 parainfluenza virus, after cardiac surgery, 84–86
- Inflammatory response, to cardiopulmonary bypass**
 in Korean population, 646–650
 pathogenesis of, 223–231
 sevoflurane effects on, 639–645
 treatment of, 384–393, 431–432
- Inhibitors, in hemophilia A, ventricular septal defect repair in, activated factor VII for, 679–681**
- Insulin, for glycemic control, 901–908**
- Intensive care**
 after aortic arch surgery, 789–794
 after CABG surgery, epidural anesthesia effects on, 807–812
 extracorporeal membrane oxygenation in, 886–892
 fellowship training for, 110–114
 pneumonia incidence and risk in, 780–788
- Interagency Registry for Mechanical Assisted Circulatory Support, 742–743**
- Intercostal arteries, transesophageal echocardiography of, 699**
- Interleukin(s), in cardiopulmonary bypass pathogenesis, 227–229, 639–645**
- Interleukin-2 blockers, for heart transplantation, 744–745**
- Intra-aortic balloon pump**
 for CABG surgery, 262–263, 479–483
 for cardiac graft failure, 203–205
- Ischemia-reperfusion injury, desflurane-induced cardioprotection in, 600–606**
- Ischemic preconditioning. *See* Preconditioning**
- Isoflurane, for preconditioning**
 mortality rate from, 594–599
 xenon interactions with, 614–618
- Jarvic 2000 Flow Maker, three-dimensional echocardiographic assessment of, 703–704
- Jet ventilation, for off-pump single-lung transplantation, 846–849**
- Jugular vein**
 internal, cannulation of, mediastinal hematoma due to, 682–683
 transesophageal echocardiography of, 697–698
- Ketamine**
 for delirium, after cardiopulmonary bypass, 651–657
 for electrophysiologic testing, 373–378
- Ketanserin, hemodynamic effects of, 95–101**
- Kidney**
 dysfunction or failure of
 in cardiac surgery, 188–194
 lipocalin measurements in, 195–199
 after pneumonectomy, 219–222
 prevention of, 434
 preventive natriuretic peptide for, 151–160
 from pulmonary artery catheter injury, 379–380
 valvular disease with, 253–255
 with ventricular assist devices, 743

Kidney (*Continued*)

- transplantation of, cardiac surgery after, 8–13
- Kininogen, in cardiopulmonary bypass pathogenesis, 224–225
- Klebsiella pneumoniae* pneumonia, in cardiothoracic intensive care unit, 780–788

Lactate levels, after cardiac surgery, 663–667

Lactic acidosis

- during cardiac surgery, 711–719
- in cardiac surgery, 407–416

LEADERS (Limus Eluted From A Durable Versus Erodable Stent Coating) trial, 6

Left ventricular assist devices

- for heart failure, 742–743
- three-dimensional echocardiographic assessment of, 702–710

Left ventricular-assist device, for myocarditis, 87–94

Letters to the Editor

- The Accuracy of the Vigileo/FloTrac System Has Been Improved—Follow-up After a Software Update: A Blinded Comparative Study of 30 Cardiosurgical Patients, 929–931
- Acute Cardiac Tamponade During Pneumonectomy, 131–132
- The Airway Scope Is a Practical Intubation Device For a Double-Lumen Tube During Rapid-Sequence Induction, 926
- The AirwayScope: An Aid Also in Transesophageal Echocardiography Probe Placement, 275
- An Audit To Assess the Impact of New Directives About the Use of Aprotinin on Re-exploration Rates and Blood Product Usage After Adult Cardiac Surgery, 445–446
- An Epidural Hematoma After Epidural Anesthesia for Endovascular Aortic Aneurysm Repair, 580–582
- Antibiotic Prophylaxis for Cardiac Surgery: A Shift Away from Traditional Cephalosporins?, 933–935
- Are Repetitive Recruitment Maneuvers After Cardiopulmonary Bypass Beneficial?, 582–583
- Bicuspid Aortic Valve Associated With Persistent Left and Absent Right Superior Vena Cava, 579–580
- Brachial Plexus Injury After Robotic-Assisted Thoracoscopic Thymectomy, 584–586
- Central Venous Oxygen Saturation: Is It Time to Find Its Clinical Applications?, 272–273
- Coenzyme Q10 and Coronary Artery Bypass Surgery: What We Have Learned From Clinical Trials, 935–936
- Combinations of Regional Anesthetic Blocks for Femoropopliteal Bypass Surgery, 442
- Electrocardiographic Changes Simulating Myocardial Ischemia Possibly Because of Previous Lung Surgery, 440–442
- Fatal Necrotic Pancreatitis as a Rare Complication After Thoracoabdominal Aortic Surgery, 926–929
- Generalized Skin Mottling: An Early Sign of Acute Mesenteric Infarction After Cardiac Surgery, 444
- The Inability of Regional Oxygen Saturation Monitoring in a Patient With Alkaptonuria Undergoing Aortic Valve Replacement, 88
- Laryngoscope-Guided and Bougie-Aided Correct Placement of a Double-Lumen Tube in a Difficult Airway, 583–584
- Left Main Bronchial Lavage With Normal Saline Under Fluoroscopy Improved Pulmonary Mechanics in a Neonate After the Damus-Daye-Stansel Procedure, 755–757
- Levosimendan May Prevent Postoperative Atrial Fibrillation Through Anti-inflammatory and Antioxidant Modulation, 757–758
- Malignant Hyperthermia and Cardiac Surgery, 134–135
- Minitracheostomy as a Prophylactic Tool in patients with Sternal Dehiscence, 135

Letters to the Editor (*Continued*)

- A Modified “Over-the-Needle” Technique for Arterial Cannulation, 753–755
 - A Novel Use of the Air Regulator Used for Spraying Fibrin Glue in the Operating Room, 936–937
 - Patient Cooperation During General Anesthesia for Combined Carotid and Coronary Artery Surgery, 439–440
 - Rapid TEG Observation Suggests Activation of Factor VII May Overcome Argatroban-Induced Coagulopathy, 752–753
 - A Rare Cause of an Entrapped Pulmonary Artery Catheter, 273–275
 - Renal Failure and Replacement Therapy After Cardiac Surgery, 758–759
 - Renal Protection: What Should We Aim For?, 128–129
 - Respiratory Failure at home After Coronary Artery Bypass Graft Surgery Requiring Extracorporeal Membrane Oxygenation, 937–938
 - Response to Gerstein Regarding Guidelines of Antiplatelet Therapy Management, 136
 - Routine Femoral Artery Pressure Monitoring in Cardiac Surgery, 932–933
 - Sleeve Pneumonectomy, 269–270
 - Spinal Cord Imaging by Transesophageal Echocardiography, 442–443
 - Stress-Free Tracheal Tube Exchange Using the Pentax-AWS (Airway Scope), 133–134
 - A Sudden Increase in Bispectral Index Score During Carotid Endarterectomy After Shunt Infection, 129–131
 - Takotsubo Cardiomyopathy in a Liver Transplant Recipient: A Diagnosis of Exclusion?, 268–269
 - Two Cases of Tracheal Rupture After Endotracheal Intubation, 271–272
 - Unusual Right Atrium Indentation: Poststernum Closure, 751–752
 - The Use of Saline for Bronchial Cuff Inflation, 270–271
- Leukocyte(s)
- in cardiopulmonary bypass pathogenesis, 227
 - filtration of, for cardiopulmonary bypass, 387–388
- Levosimendan
- for cardiac graft failure, 203–205
 - cardioprotective effects of, 474–478
- Limus Eluted From A Durable Versus Erodable Stent Coating (LEADERS) trial, 6
- Lipocalin, in CABG surgery, 195–199
- Lipoma, atrial, 729–731
- Lobectomy
- delayed extubation after, 766–769
 - one-lung ventilation for, 770–774
- Lung
- bullae in, 911–913
 - edema of
 - after aortic valve replacement, extracorporeal membrane oxygenation for, 549–554
 - in atrial myxoma embolism, 211–214
 - function of, vs. sternotomy incision size, 795–801
 - inflammatory response in, during cardiopulmonary bypass, 639–645
 - injury of
 - persistent pneumothorax after, 369–372
 - transfusion-related, 434
 - parainfluenza virus infection of, 84–86
 - resection of
 - delayed extubation after, 766–769
 - kidney failure after, 219–222
 - one-lung ventilation for, 506–508, 770–774
 - pneumonia after, 434

- Lung (*Continued*)
 transplantation of
 jet ventilation for, 846–849
 vasodilatory shock after, 529–530
 Lymphocytes, in cardiopulmonary bypass pathogenesis, 228
- Mammary artery, internal, transesophageal echocardiography of, 698–699
 Marfan's syndrome, aortic aneurysm repair in, 71–74
 Mechanical circulatory support, for myocarditis, 87–94
 Mechanical ventilation
 pneumonia related to, 780–788
 risk factors for, after aortic arch surgery, 495–500
 Median sternotomy, for aortic valve surgery, respiratory function after, 795–801
 Mediastinal hematoma, due to internal jugular vein cannulation, 682–683
 Mediastinal schwannomas, 115–117
 Mediastinitis, due to central venous catheter venous perforation, 672–674
 Medos VAD system, for myocarditis, 87–94
 Memory processing, during propofol-remifentanyl anesthesia, 175–181
 Mesenteric artery, superior, transesophageal echocardiography of, 699–700
 Metabolic acidosis, during cardiac surgery, 711–719
 Methemoglobin, coagulation effects of, 41–47
 Methylene blue, for shock, after lung transplantation, 529–530
 Methylprednisolone, as anti-inflammatory agent, for cardiopulmonary bypass, 431
 Metoprolol, for noncardiac surgery, clinical trials of, 684–693
 Microcirculation, hemodynamics of, ketanserin effects on, 95–101
 Milrinone
 for cardiopulmonary bypass, 386
 for graft blood flow, 48–53
 for heart failure, 741
 Minimally invasive cardiac surgery
 aortic valve replacement, 573, 795–801
 mitral valve, 920–921
 reexpansion pulmonary edema after, 549–554
 reimbursement for, 142–146
 Ministernotomy, for aortic valve surgery, respiratory function after, 795–801
 Mitral valve
 calcification of, in kidney failure, 253–255
 dysfunction of
 intraoperative classification for, 531–543
 progress in, 916–923
 regurgitation of
 assessment of, under general anesthesia, 555–560
 functional, 572–573
 repair of
 intraoperative classification for, 531–543
 progress in, 916–923
 tricuspid regurgitation after, 251–252
 replacement of, 5
 left atrial “v” waves after, 69–70
 progress in, 919–920
 with pulmonary arterial hypertension, 298–305
 stenosis of, in kidney failure, 253–255
 Monocytes, in cardiopulmonary bypass pathogenesis, 228
 Morphine
 for cardiopulmonary bypass, 386
 for helium preconditioning, 619–624
 for postoperative pain, 170–174
 for spinal analgesia, for cardiac surgery, 813–821
 Morquio syndrome, aortic valve replacement in, 855–857
- Mortality
 in cardiac surgery
 B-natriuretic peptide levels and, 147–150
 CABG, 870
 coronary revascularization, 261–263
 Fontan procedure, 54–61
 with heart failure, 741–742
 with intra-aortic balloon pump, 479–483
 after kidney transplantation, 8–13
 natriuretic peptide effects on, 151–160
 from retained surgical sponge, 102–109
 spinal analgesia effects on, 813–821
 statin effects on, 263, 431–432, 468–473, 633–638
 transesophageal echocardiography-related, 62–65
 volatile anesthesia effects on, 594–599
 in heart failure, 742–743
 Motion artifacts, in radiography, 909–910
 Moyamoya disease, cardiopulmonary bypass for, 206–207
 MP4 (Hemospan), for hemodilution, 339–347
 Mucopolysaccharidosis, aortic valve replacement in, 855–857
 Multisystem organ failure, in cardiac surgery, ethyl pyruvate effects on, 324–329
 Myocardial ischemia
 with aortic dissection, 732–734
 reduction of, preconditioning for. *See* Preconditioning
 Myocarditis, mechanical circulatory support for, 87–94
 Myocardium
 functional assessment of, echocardiography in, 462–467
 preconditioning of. *See* Preconditioning
 Myxomas, atrial
 embolism from, 211–214
 in septum, 424–426
 transesophageal echocardiography in, 66–68
- Natriuretic peptides, in cardiac surgery
 as heart failure predictor, 161–165
 for kidney dysfunction prevention, 151–160
 as outcome predictor, 147–150
 Near-infrared spectroscopy
 for lactate measurement, after cardiac surgery, 663–667
 for status epilepticus detection, after cardiac surgery, 668–671
 Neutrophils, in cardiopulmonary bypass pathogenesis, 227–228
 Newborns, cardiac surgery in, subglottic stenosis related to, 658–662
 Nitric oxide products, urinary, in cardiac surgery, 188–194
 Nitroprusside, for cardiopulmonary bypass, 386
 Noncompaction cardiomyopathy, 200–202
 Novacor devices, three-dimensional echocardiographic assessment of, 702–703
 NovoSeven (Factor VIIa), for blood loss, in cardiac surgery, 28–33, 34–40
- Obesity, femoral thrombectomy in, 522–525
 Off-pump CABG. *See* Coronary artery bypass graft (CABG) surgery, off-pump
 Omega-3 fatty acids, for cardioprotection, 434
 One-lung ventilation
 alveolar recruitment in, 506–508
 arterial oxygenation and, 770–774, 775–779
 bronchial blockers for, 860–868
 devices for, 501–505
 end-tidal carbon dioxide in, 775–779
 hypoxemia treatment during, 850–852
 Opioid receptors, in helium preconditioning, 619–624
 Orthopnea, continuous positive airway pressure for, 522–525

Outcomes

- of beta blockade in noncardiac surgery, 684–693
- of CABG surgery, 261–263
 - with intra-aortic balloon pump, 479–483
 - statin effects on, 263, 431–432, 468–473, 633–638
 - white blood cell count and, 484–487
- of cardiac surgery
 - blood transfusion effects on, 22–27
 - B-natriuretic peptide levels and, 147–150
 - cognitive function, 14–21
 - coronary revascularization, 261–263
 - coronary stenting, 261–262
 - C-reactive protein levels and, 166–169
 - with extracorporeal membrane oxygenation for adults, 886–892
 - with factor VIIa treatment, 29–33, 34–40
 - glycemic control and, 901–908
 - after kidney transplantation, 8–13
 - milrinone effects on, 48–53
 - mitral valve replacement with pulmonary hypertension, 298–305
 - natriuretic peptide effects on, 151–160, 161–165
 - with one-lung ventilation, 770–774
 - percutaneous aortic valve replacement, 280–285, 286–291
 - pulmonary artery flow patterns and, 54–61
 - spinal anesthesia and, 813–822
 - sternal incision size and, 795–801
 - volatile anesthesia effects on, 594–599
 - wound infections and, 488–494
- of early extubation, in pediatric patients, 348–357
- of ethyl pyruvate for multisystem organ failure prevention, 324–329
- of heart failure treatment, 738–743
- of hemodilution, 329–347
- of resynchronization therapy, after cardiac surgery, 306–311
- Oximetry, after cardiac surgery, 663–667
- Oxygenation, in one-lung ventilation, 770–774, 850–852

- Pacing, after CABG surgery, 306–311
- Pain, shoulder, after thoracic surgery, 853–854
- Papillary muscle, calcification of, 118–120
- Paracorporeal devices, for myocarditis, 87–94
- Parainfluenza virus pneumonia, after cardiac surgery, 84–86
- Parenteral nutrition, catheter perforation during, mediastinitis due to, 672–674
- Partial left-heart bypass, for aortic aneurysm, 893–900
- Patient-controlled pain management, after cardiac surgery, 170–174
- Pectus excavatum repair, inferior vena cava obstruction after, 515–517
- Pediatric patients. *See also* Congenital heart disease
 - cardiac surgery in
 - extubation timing in, 348–357
 - intraoperative assessment of, 79–81
 - lactate levels after, 663–667
 - left atrial “v” waves after, 69–70
 - pulmonary artery flow patterns after, 54–61
 - status epilepticus after, 668–671
 - subglottic stenosis related to, 658–662
 - for ventricular septal defect, 675–678, 679–681
 - lung transplantation in, shock in, 529–530
 - one-lung ventilation for, 866–867
 - pectus excavatum repair in, inferior vena cava obstruction after, 515–517
- Pericarditis, constrictive, mitral valve regurgitation with, 251–252
- Perioperative beta-blockade (POBBLE) trial, 684–693
- PeriOperative ISchemic Evaluation (POISE) trial, for beta blockade in noncardiac surgery, 432, 684–693, 741
- Pexelizumab, for cardiopulmonary bypass, 386

- Phosphodiesterase inhibitors
 - for cardiopulmonary bypass, 386
 - for heart failure, 741
- Planimetry, for aortic stenosis, 870–871
- Plasminogen, in cardiopulmonary bypass pathogenesis, 226–227
- Platelet(s)
 - in cardiopulmonary bypass pathogenesis, 228–229
 - resistance to, 6
- Pneumonectomy
 - delayed extubation after, 766–769
 - kidney failure after, 219–222
 - one-lung ventilation for, 770–774
- Pneumonia
 - in cardiothoracic intensive care unit, 780–788
 - parainfluenza virus, after cardiac surgery, 84–86
 - postoperative, prevention of, 434
- Pneumothorax
 - vs. giant bullous emphysema, 911–913
 - after tracheobronchial injury, 369–372
- Polyostotic fibrous dysplasia, chest wall resection for, 518–521
- Porphyria, acute intermittent, cardiac surgery in, 364–368
- Postoperative pain, for cardiac surgery, patient-controlled, 170–174
- Preconditioning
 - advances in, 3–4, 433–434
 - esmolol for, 625–632
 - helium for, opioid receptor effects on, 619–624
 - volatile anesthetics for
 - beta-adrenergic receptors and, 607–613
 - mortality rate from, 594–599
 - timing of, 600–606
 - xenon effects on, 614–618
- Pregnancy, noncompaction cardiomyopathy discovery during, 200–202
- Prekallikrein, in cardiopulmonary bypass pathogenesis, 224–225
- Premature ventricular contraction, ablation of, airway interventions for, 841–845
- Pressure-controlled ventilation, arterial oxygenation with, 770–774
- Propofol
 - for cardiac surgery, 878–885
 - memory processing during, 175–181
 - one-lung ventilation with, 775–779
 - pharmacokinetics of, with left ventricular dysfunction, 182–187
- Prosthetic aortic valve, endocarditis of, 561–563
- Protein C, activated, for cardiac surgery, 858–859
- Pseudomonas aeruginosa* pneumonia, in cardiothoracic intensive care unit, 780–788
- Pulmonary artery
 - flow patterns in, after Fontan procedure, 54–61
 - tumor embolism in, 77–78
- Pulmonary catheter, kidney injury from, 379–380
- Pulmonary edema
 - after aortic valve replacement, extracorporeal membrane oxygenation for, 549–554
 - in atrial myxoma embolism, 211–214
- Pulmonary embolism, in right heart failure, 741
- Pulmonary hypertension
 - after mitral valve replacement, 69–70
 - mitral valve replacement with, 298–305
- Pulmonic valve, fibroelastomas of, 358–359
- Pulse contour method, for cardiac output monitoring, 401–406

- Radiation therapy, mitral valve damage in, repair of, 251–252
- Radiography
 - for giant bullous emphysema, 911–913
 - motion artifacts in, 909–910

- Recombinant activated factor VII therapy, monitoring of, with thromboelastography, 828–834
- Reconstructive Endovascular Surgery returning Torsion Original Elliptical shape to the LV group (RESTORE), 739–740
- Red blood cell transfusions
 advances in, 4–5
 for cardiac surgery, atrial fibrillation development and, 22–27
- Reexpansion pulmonary edema, after aortic valve replacement, extracorporeal membrane oxygenation for, 549–554
- Reimbursement, for minimally invasive surgery, 142–146
- Relaxin, for heart failure, 740
- Remifentanyl
 memory processing during, 175–181
 for postoperative pain, 170–174
- Renal artery, transesophageal echocardiography of, 699
- Reperfusion injury, desflurane-induced cardioprotection in, 600–606
- Resistance training, anabolic steroid use for, cardiac abnormalities due to, 208–210
- Respiratory function, vs. sternotomy incision size, 795–801
- Respiratory support, extracorporeal membrane oxygenation for, 886–892
- Resynchronization therapy
 after CABG surgery, 306–311
 for heart failure, 741
- Retrograde cerebral perfusion, in aortic arch surgery, 417–420
- Rewarming, after cardiac surgery, cognitive function and, 14–21
- Rheumatic heart disease, mitral valve replacement for, 298–305
- Robotic surgery, 407–416
- Saline distention technique, for valve repair assessment, 79–81
- Schwannomas, mediastinal, 115–117
- Sedation, for electrophysiology procedures, 841–845
- Selectins, in cardiopulmonary bypass pathogenesis, 228
- Septic shock, activated protein C for, 858–859
- Sequential Organ Failure Assessment score, for pneumonia, 780–788
- Sevoflurane
 for inflammatory response reduction, in cardiopulmonary bypass, 639–645
 one-lung ventilation with, 775–779
 for preconditioning, mortality rate from, 594–599
- Shock
 aprotinin-induced, hemofiltration for, 526–528
 in lung transplantation, methylene blue for, 529–530
 septic, activated protein C for, 858–859
- Shone's anomaly, diagnosis of, 75–76
- Shoulder pain, after thoracic surgery, 853–854
- Sildenafil, for heart transplantation, 744
- Simulator, for transesophageal echocardiography, 544–548
- Sinus of Valsalva, aneurysm of, rupture into atrium, 735–737
- Sitaxsentan, for cardiac surgery, 432
- Situs inversus, congenitally corrected transposition of the great arteries with, 239–244
- Sodium nitroprusside, for cardiopulmonary bypass, 386
- Speckle tracking, in myocardial functional assessment, 462–467
- Spinal analgesia, for cardiac surgery, 813–821
- Sponges, surgical, hemodynamic instability due to, 102–109
- Staphylococcus aureus* pneumonia, in cardiothoracic intensive care unit, 780–788
- Statins, before and/or after CABG surgery, 263, 431–432, 468–473, 633–638
- Status epilepticus, after cardiac surgery, near-infrared spectroscopy detection of, 668–671
- Stents
 carotid, vs. endarterectomy, 245–250
- Stents (*Continued*)
 coronary artery
 drug-eluting, 5–6
 outcomes of, 261–262
 femoropopliteal artery, 432–433
- Sternal infections, after cardiac surgery, epidemiology of, 488–494
- Sternotomy, for aortic valve surgery, respiratory function after, 795–801
- Steroids, performance-enhancing, cardiac abnormalities due to, 208–210
- Stress testing, in coronary artery disease, preprocedural, 259–260
- Subclavian artery, transesophageal echocardiography of, 697–698
- Subglottic stenosis, in cardiac surgery, 658–662
- Supraventricular tachycardia, ablation of, airway interventions for, 841–845
- Surgical sponges, hemodynamic instability due to, 102–109
- Surgical Treatment for Ischemic Heart Failure (STICH) trial, 740
- Surgical ventricular restoration, for heart failure, 739–740
- Systemic inflammatory response, to cardiac surgery
 erythropoietin effects on, 316–323
 treatment of, 431–432
- T cells, in cardiopulmonary bypass pathogenesis, 228
- Tacrolimus, for heart transplantation, 744
- TandemHeart, three-dimensional echocardiographic assessment of, 704
- Temperature, of fluids, for cardiopulmonary bypass, 388
- Thermal coronary angiography, for coronary artery graft patency verification, 233
- Thermodilution, for cardiac output measurement, under general anesthesia, 836–840
- Thoracic surgery
 arterial oxygenation in, 775–779
 cervicogenic shoulder pain after, 853–854
 delayed extubation after, 766–769
 for fibrous dysplasia, 518–521
 high-frequency jet ventilation in, 509–512
 hypoxemia in, 850–852
 inferior vena cava obstruction after, 515–517
 jet ventilation for, 846–849
 lung resection, kidney failure after, 219–222
 lung transplantation, 529–530, 846–849
 one-lung ventilation for
 alveolar recruitment in, 506–508
 arterial oxygenation and, 770–774
 devices for, 501–505
 pneumonia in, 780–788
 for schwannoma, 115–117
- Thoracoscopy, hypoxemia in, 850–852
- Thorotomy, delayed extubation after, 766–769
- Thoratec devices, three-dimensional echocardiographic assessment of, 702–703
- Thrombin, in cardiopulmonary bypass pathogenesis, 224–225
- Thromboelastography/thromboelastometry
 in coagulation studies, methemoglobin and, 41–47
 for guiding recombinant activated factor VII therapy, 828–834
- Thrombosis and thrombi
 of left atrium, 566–568
 removal of, in obesity with chronic obstructive pulmonary disease, 522–525
 from tumor, 77–78
- Tissue factor, in cardiopulmonary bypass pathogenesis, 225, 228
- Trachea
 injury of
 conservative management of, 513–514
 persistent pneumothorax after, 369–372
 obstruction of, from mediastinal hematoma, 682–683

- Tracheostomy, bronchial blockers with, 865
- Training. *See* Education
- Tranexamic acid
for CABG surgery, 312–315
clinical trials of, 2–3
- Transcatheter mitral valve repair, 920–921
- Transesophageal echocardiography
of aorta and branches, 694–701
for aortic aneurysm repair, 71–74
for aortic dissection, 427–428, 732–734
for aortic root ulcer, 564–565
for aortic valve replacement, 292–297
for atrial lipoma, 729–731
for atrial septal myxoma, 424–426
for atrial thrombus, 566–568
for central venous catheter position verification, 457–461
complications of, 62–65
for coronary sinus of Valsalva aneurysm, 421–423
for inverted left atrial appendage, 914–915
for mitral valve repair, 531–543
for myocardial functional assessment, 462–467
for prosthetic aortic valve endocarditis, 561–563
for pulmonic valve fibroelastoma, 358–359
for retained sponge detection, 102–109
for right atrial fistula, 360–363
for Shone's anomaly, 75–76
for sinus of Valsalva aneurysm, 735–737
three-dimensional, in atrial myxoma, 66–68
training simulator for, 544–548
for tumor embolization, 77–78
for valve repair assessment, 79–81
for ventricular septal defect, 675–678
- Transfusions, 394–400
advances in, 4–5
atrial fibrillation development and, 22–27
blood substitutes for, 339–347
blood supply for, carboxyhemoglobin in, 336–338
lung injury in, 434
minimization of, 388
preoperative immune response and, 330–335
- Transit time-flow measurement, for coronary artery graft patency verification, 234–236
- Transplantation
heart
alternatives to, 745
immunosuppression for, 744–745
lactic acidosis during, 711–719
primary graft failure after, 203–205
progress in, 743–745
psychosocial factors in, 745
right ventricular function after, 744
surgical technique for, 744–745
kidney, cardiac surgery after, 8–13
lung
jet ventilation for, 846–849
vasodilatory shock after, 529–530
- Transposition of the great arteries, congenitally corrected, 239–244
- Transthoracic echocardiography, focused, 450–456
- Trauma, persistent pneumothorax after, 369–372
- Tricuspid valve
regurgitation of
after mitral valve repair, 251–252
vs. ventricular septal defect with left ventricular-to-right atrial shunt, 675–678
- Tricuspid valve (*Continued*)
vena cava filter migration to, 381–383
- Troponin, postoperative levels of, levosimendan effects on, 474–478
- Tumor(s)
atrial
embolism from, 211–214
transesophageal echocardiography in, 66–68
embolism from
atrial, 211–214
in inferior vena cava, 77–78
in pneumonectomy, 219–222
mediastinal, 115–117
pulmonic valve, 358–359
- Tumor necrosis factor- α
blockade of, for cardiac surgery, 432
in cardiopulmonary bypass pathogenesis, 227–229
polymorphisms in, 646–650
sevoflurane effects on, 639–645
in heart failure pathophysiology, 740
- Ulcer, of aortic root, 564–565
- Ultrafiltration, for cardiopulmonary bypass, 387
- Ultrasonography
for central venous catheter insertion, 720–728
for coronary artery graft patency verification, 236
- Ultrasound dilution method, for cardiac output measurement, under
general anesthesia, 836–840
- Uniblocker, 861–862
- Univent bronchial blocker, 861–862
- Valvular heart disease. *See also specific valves*
assessment of, under general anesthesia, 555–560
in kidney failure, 253–255
surgery for
activated protein C after, 858–859
with acute intermittent porphyria, 364–368
advances in, 5, 569–576
aortic valve replacement, 280–285, 286–291
brain natriuretic peptide levels after, 161–165
cerebral protection in, 417–420
C-reactive protein levels after, 166–169
epicardial echocardiography in, 292–297
intraoperative assessment of, 79–81
intraoperative classification for, 531–543
left atrial “v” waves after, 69–70
mitral valve repair, 251–252
in Morquio syndrome, 855–857
multisystem organ failure in, ethyl pyruvate effects on, 324–329
percutaneous aortic valve replacement, 280–285, 286–291
with pulmonary arterial hypertension, 298–305
pulmonary edema after, extracorporeal membrane oxygenation for, 549–554
right atrial fistula after, 360–363
- Vanishing-lung syndrome (giant bullous emphysema), 911–913
- Vascular surgery. *See* Carotid endarterectomy; *procedures on aorta*
- Vena cava
filters for, intracardiac migration of, 381–383
inferior
obstruction of, after pectus excavatum repair, 515–517
tumor embolism in, 77–78
- Ventilation
high-frequency jet, for esophagectomy, 509–512
jet, for off-pump single-lung transplantation, 846–849
one-lung
alveolar recruitment in, 506–508

Ventilation (*Continued*)

- arterial oxygenation and, 770–774, 775–779
- bronchial blockers for, 860–868
- devices for, 501–505
- end-tidal carbon dioxide in, 775–779
- hypoxemia treatment during, 850–852
- pneumonia associated with, 780–788
- risk factors for, after aortic arch surgery, 495–500

VentrAssist device, three-dimensional echocardiographic assessment of, 704

Ventricle(s)

left

- aneurysm of, 118–120
- dysfunction of, propofol pharmacokinetics in, 182–187
- dyssynchrony of, after CABG surgery, 306–311
- function of, three-dimensional echocardiographic assessment of, 704–705
- hypertrophy of, in anabolic steroid use, 208–210
- surgical reconstruction of, for heart failure, 739–740

right, function of

- assessment of, 90–92, 705
- after heart transplantation, 744

Ventricular assist devices, for heart failure, 742–743

Ventricular septal defect

- left ventricular-to-right atrial shunt with, 675–678
- repair of, in hemophilia A, activated factor VII for, 679–681

Ventricular tachyarrhythmias

- ablation of, airway interventions for, 841–845
- electrophysiologic testing of, ketamine for, 373–378

Vigileo device, for cardiac output monitoring, 401–406

Volatile anesthetics, for preconditioning

- beta-adrenergic receptors and, 607–613
- mortality rate from, 594–599
- timing of, 600–606

Volume-controlled ventilation, arterial oxygenation with, 770–774

von Willebrand factor, in cardiopulmonary bypass pathogenesis, 228

White blood cell(s), in cardiopulmonary bypass pathogenesis, 227

White blood cell count, after cardiac surgery, atrial fibrillation development and, 22–27, 484–487

Wound infections, after cardiac surgery, epidemiology of, 488–494

Xenon, in isoflurane cardioprotection, 614–618